Know Cancer

or
forgot password

A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome

Thank you

Trial Information

A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma


PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of carfilzomib, both as a single agent as
well as in combination with romidepsin, in patients with cutaneous T-cell lymphoma (CTCL).

SECONDARY OBJECTIVES:

I. Overall response rate (ORR). II. Duration of response. III. Time to progression (TTP).

TERTIARY OBJECTIVES:

I. Measure proteasome activity concurrently in peripheral blood mononuclear cells (PBMCs)
and tumor tissue biopsy specimens in order to gather pilot data on proteasome inhibition in
CTCL patients treated with carfilzomib alone as well as carfilzomib with romidepsin.

OUTLINE: This is a dose-escalation study of carfilzomib. Patients are randomized to 1 of 2
treatment arms.

ARM A: Patients receive carfilzomib intravenously (IV) over 30 minutes on days 1, 2, 8, 9,
15, and 16.

ARM B: Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8,
and 15.

In both arms, treatment repeats every 28 days for at least 2-4 courses in the absence of
disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 1
year.


Inclusion Criteria:



- Patients must have histological confirmation of a cutaneous T-cell lymphoma (CTCL) of
any histology; confirmation of histological diagnosis must be completed prior to
enrollment by the lead site (Northwestern)

- Patients will be stratified by mycosis fungoides (MF) and Sezary syndrome (SS)
(report diagnostic or consistent with MF/SS), stage IA-IVB according to TNM
blood (TNMB) classification versus other CTCL histologies

- Patients must have measurable disease (using modified Severity-Weighted Assessment
Tool [mSWAT]) and/or use of indicator lesions must be designated prior to study
enrollment (from imaging); measurable disease upon physical exam with a negative scan
is acceptable

- Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status
of =< 2

- Patients must have a life expectancy of >= 3 months

- Patients with MF/SS must have failed at least 1 prior topical therapy (including
steroids, nitrogen mustard, retinoids, phototherapy, photochemotherapy, radiation,
and total skin electron beam); there is no upper limit for prior therapies

- Serum creatinine =< 2.0 mg/dL

- Total bilirubin =< 2.2 mg/dL

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2 x
upper limit of normal (ULN)

- Leukocytes >= 3,000/mm^3

- Absolute neutrophils >= 1,500/mm^3

- Platelets >= 100,000/mm^3

- Patients must have an electrocardiogram (EKG) demonstrating QTc =< 500 ms within 28
days prior to registration

- Females of child-bearing potential and sexually active males must agree to use
effective methods of contraception:

- Child-bearing potential is defined as any woman (regardless of sexual
orientation, having undergone a tubal ligation, or remaining celibate by choice)
who meets the following criteria:

- Has NOT undergone a hysterectomy or bilateral oophorectomy; OR

- Has NOT been naturally menopausal for at least 12 consecutive months (i.e.
has had menses at any time in the preceding 12 consecutive months)

- The effectiveness of hormonal contraceptives may be reduced by romidepsin, thus
effective methods should include at least 1 form of barrier contraception

- Females of child-bearing potential must have a negative pregnancy test within 7 days
prior to registration

- Patients must be disease free of any prior malignancies for >= 3 years

- The exception to this would be currently treated squamous cell and basal cell
carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or
surgically removed melanoma in situ of the skin (stage 0) with histologically
confirmed free margins of excision

- Patients must give written informed consent prior to registration on the study

Exclusion Criteria:

- Patients who have received topical therapy, systemic chemotherapy, or biological
therapy within 4 weeks prior to registration are NOT eligible for participation

- Patients who have undergone major surgery within 21 days prior to registration are
NOT eligible for participation

- Patients who have an acute active infection requiring treatment (systemic
antibiotics, antivirals, or antifungals) within 14 days prior to registration are NOT
eligible for participation

- Patients in whom IV fluid hydration is contraindicated (e.g. due to pre-existing
pulmonary, cardiac, or renal impairment) will NOT be eligible for participation

- Patients who are pregnant and/or lactating are NOT eligible for participation

- Patients who have had a prior stem cell transplantation are NOT eligible for
participation

- Patients who have had any of the following cardiac conditions are NOT eligible for
participation (unless otherwise noted):

- Unstable angina or myocardial infarction within 4 months prior to registration

- New York Heart Association (NYHA) class II or IV heart failure

- Uncontrolled angina

- A history of severe coronary artery disease

- Severe, uncontrolled ventricular arrhythmias

- Sick sinus syndrome

- Electrocardiographic evidence of acute ischemia or Grade 3 conduction system
abnormalities UNLESS the patient has a pacemaker

- Patients who exhibit uncontrolled hypertension (>= 140/90 mmHg) or uncontrolled
diabetes within 14 days prior to registration are NOT eligible for participation

- Patients who have experienced significant neuropathy (grades 3-4 or grade 2 with
pain) within 14 days prior to registration are NOT eligible for participation

- Patients who have a known history of allergy to Captisol (a cyclodextrin derivative
used to stabilize carfilzomib) are NOT eligible for participation

- Patients who have a contraindication to any of the required concomitant drugs or
supportive treatments (including hypersensitivity to all anticoagulation and
antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting
pulmonary or cardiac impairment) are NOT eligible for participation

- Patients with pleural effusions requiring thoracentesis or ascites requiring
paracentesis within 14 days prior to registration are NOT eligible for participation

- Patients who have any serious condition, laboratory abnormality, or psychiatric
illness that would prevent them from singing the informed consent form are NOT
eligible for participation

- Patients who have had prior exposure to romidepsin or any proteasome inhibitor are
NOT eligible for participation

- Patients with a known human immunodeficiency virus (HIV) infection are NOT eligible
for participation

- Patients who test positive for infectious hepatitis types A, B, or C within 14 days
of registration are NOT eligible for participation

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate toxicity by assessing the adverse events of carfilzomib alone and when taken with romidepsin

Outcome Description:

To determine the maximum tolerated dose (MTD) by assessing the adverse events of both carfilzomib alone and when taken with romidepsin in evaluating toxicity on days 1 and 15 of each cycle of treatment

Outcome Time Frame:

During the first 28 days (1 cycle=28 days)

Safety Issue:

Yes

Principal Investigator

Timothy Kuzel

Investigator Role:

Principal Investigator

Investigator Affiliation:

Northwestern University

Authority:

United States: Institutional Review Board

Study ID:

NU 12H06

NCT ID:

NCT01738594

Start Date:

January 2013

Completion Date:

Related Keywords:

  • Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
  • Recurrent Mycosis Fungoides/Sezary Syndrome
  • Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage IA Mycosis Fungoides/Sezary Syndrome
  • Stage IB Mycosis Fungoides/Sezary Syndrome
  • Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage IIA Mycosis Fungoides/Sezary Syndrome
  • Stage IIB Mycosis Fungoides/Sezary Syndrome
  • Stage III Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage IIIA Mycosis Fungoides/Sezary Syndrome
  • Stage IIIB Mycosis Fungoides/Sezary Syndrome
  • Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage IVA Mycosis Fungoides/Sezary Syndrome
  • Stage IVB Mycosis Fungoides/Sezary Syndrome
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Mycoses
  • Mycosis Fungoides
  • Sezary Syndrome
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous

Name

Location

Northwestern UniversityChicago, Illinois  60611